AR and prostate carcinoma: The combination of ENZ and the ferroptosis inducer RSL3 was particularly effective in reducing tumor growth in CRPC models, suggesting that targeting AR signaling can potentiate ferroptosis, thereby offering a promising therapeutic avenue for advanced prostate cancer.